HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $82.00 price target on the stock. APLS has been the topic of several other research reports. Wells Fargo & Company decreased their target price on […]
Oppenheimer reissued their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. APLS has been the subject of a number of other research reports. Robert W. Baird lowered their price target on Apellis Pharmaceuticals from $115.00 to $70.00 and set an outperform […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Wedbush from $32.00 to $29.00 in a research note released on Monday, Benzinga reports. The firm currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $2.19 EPS and FY2027 earnings at $3.12 EPS. A […]
Bank of America cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a buy rating to a neutral rating in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. They currently have $40.00 target price on the stock, down from their previous target price of $114.00. APLS has been the subject […]